Sean Taasan, MD

Published Articles (2)

Cellular Therapies for Multiple Myeloma Part II: CAR-T Toxicities for the Community Oncologist

July 3, 2026

While ide-cel and cilta-cel are generally considered safe and have remarkable therapeutic impact for relapsed/refractory myeloma, both agents carry a broad and clinically significant toxicity burden that practitioners must recognize and actively surveil.

Cellular Therapies for Multiple Myeloma Part I: A CAR-T Primer for the Community Oncologist

July 2, 2026

Ide-cel was the first anti-BCMA CAR-T product approved by the FDA in March 2021, employing a single anti-BCMA single-chain variable fragment.